Tempus AI Inc（納斯達克股票代碼：TEM）週一收盤後公佈了第四季度財務業績。以下是本季度的關鍵指標。 第四季度業績：Tempus AI 報告第四季度收入爲2.0068億美元，低於預期的2.0312億美元。這家專注於AI精密醫學和患者護理的公司報告第四季度調整後每股虧損18美分，超出分析師預期的每股虧損20美分。 總收入同比增長35.8%，數據和服務收入增長44.6%，至8020萬美元。基因組學同比增長30.6%，至1.204億美元，單元增長同比達到22.5%。 Tempus AI表示，公司在季度末合約價值總額爲9.4億美元，淨收入保留率爲140%。公司在季度末擁有約3.4095億美元的現金及現金等價物。 Tempus AI 的創始人兼首席執行官 Eric Lefkofsky 表示：“我們相信對AI的投資已使我們在未來佔據有利位置，幾年之前看似不可想象的技術現在越來越多地使我們能夠實現智能診斷，幫助患者過上更長壽和更健康的生活。我們仍然有信心實現主要財務目標，預計2025年收入將強勁增長並實現正的調整後EBITDA。” 指導意見：Tempus AI 預計2025年全年的合併收入約爲12.4億美元，同比增長約79%。根據Benzinga Pro 的估計，分析師預計全年的收入將爲10.2億美元。 公司預計2025年全年調整後EBITDA爲500萬美元，而2024年全年調整後EBITDA虧損爲1.047億美元。 管理層將在北京時間週一下午4:30舉行的電話會議上進一步討論公司的季度表現。 TEM 股價表現：截至公佈前，Tempus AI 股價年初至今已上漲逾105%。自前任衆議院議長南希·佩洛西披露購買幾筆2026年到期的看漲期權以來，股票在最近幾周受到更多關注。 根據 Benzinga Pro 的數據，週一盤後交易中 Tempus AI 股價下跌7.63%，至64美元。 圖片來源：Tempus AI。

以上內容來自Benzinga Earnings專欄，原文如下：

Tempus AI Inc (NASDAQ:TEM) reported fourth-quarter financial results after the market close on Monday. Here’s a look at the key metrics from the quarter.

Q4 Earnings: Tempus AI reported fourth-quarter revenue of $200.68 million, missing estimates of $203.12 million. The AI-focused precision medicine and patient care company reported a fourth-quarter adjusted loss of 18 cents per share, beating analyst estimates for a loss of 20 cents per share, according to Benzinga Pro.

Total revenue was up 35.8% year-over-year as data and services revenue grew 44.6% to $80.2 million. Genomics grew 30.6% year-over-year to $120.4 million and unit growth came in at 22.5% year-over-year.

Tempus AI said it ended the quarter with $940 million in total remaining contract value and 140% net revenue retention. The company had approximately $340.95 million in cash and equivalents at quarter’s end.

“We believe our investments in AI have positioned us well for the future, as technologies that seemed unimaginable a few short years ago increasingly allow us to make our diagnostics intelligent, helping patients live longer and healthier lives. We remain on track to achieve our key financial milestones, with expected robust revenue growth and positive Adjusted EBITDA in 2025,” said Eric Lefkofsky, founder and CEO of Tempus AI.

Check This Out: Salesforce & Google Supercharge AI: New Partnership Unlocks Next-Gen Business Automation

Guidance: Tempus AI expects full-year 2025 revenue of approximately $1.24 billion for its consolidated Tempus and Ambry Genetics business, which represents approximately 79% annual growth. Analysts are looking for full-year revenue of $1.02 billion, according to Benzinga Pro estimates.

The company said it anticipates a full-year 2025 adjusted EBITDA of $5 million, versus a full-year adjusted EBITDA loss of $104.7 million in full-year 2024.

Management will further discuss the company’s quarterly performance on a conference call that kicks off at 4:30 p.m. ET.

TEM Price Action: Tempus AI shares were up more than 105% year-to-date heading into the print. The stock has seen increased attention in recent weeks since former House Speaker Nancy Pelosi disclosed the purchase of several call options that don’t expire until 2026.

Tempus AI shares were down 7.63% after hours, trading at $64 at the time of publication Monday, according to Benzinga Pro.

Photo: Courtesy of Tempus AI.